Default Category
-
Terumo (C) (Spanish Version)
Godes, David B.; Egawa, Masako; Yamazaki, MayukaCase HBS-510S03MarketingPara maximizar su eficacia, los casos de color deben imprimirse en color. Este caso proporciona una información actualizada sobre la decisión de la empresa en cuanto a su estrategia de ventas para sus productos de EE.UU. catéter y el progreso del paquete de soluciones. También se analiza la expansión de la firma del "Pranex médica", una formación y reunión espacio único que ofrece facilidad para médicos y enfermeras.Starting at €5.74
-
Terumo (A)
Godes, David B.; Egawa, Masako; Yamazaki, MayukaCase HBS-508068-EMarketingTo maximize their effectiveness, color cases should be printed in color. Terumo faces two challenges: how to sell its catheter products in the U.S. and its new "Solution Pack" in its domestic market, Japan. The case provides rich detail on the firm's evolution from a manufacturer of thermometers to a seller of commodity products like syringes to a diversified firm offering a range of advanced products-catheters and graphs, for example-in addition...Starting at €8.20
-
Terumo (B)
Godes, David B.; Egawa, Masako; Yamazaki, MayukaCase HBS-508069-EMarketingThis case provides an update on the firm's decision regarding its U.S. sales strategy for its catheter products and the progress of Solution Pack.Starting at €5.74
-
Merck: La administración de Vioxx (D)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S05Knowledge and CommunicationStarting at €5.74
-
Pfizer: Letter from the Chairman (B)
Simons, Robert L.; Rosenberg, KathrynCase HBS-110004-EAccounting and ControlThis case continues the story begun in "Pfizer: A Letter From The Chairman" (HBS No. 9-110-003), revealing the letter Chairman and CEO Jeff Kindler wrote for the 2008 Annual Report.Starting at €5.74
-
Pfizer: Letter from the Chairman (A) and (B), Teaching Note
Simons, Robert L.; Rosenberg, KathrynTeaching Note HBS-110067-EAccounting and ControlTeaching Note for 110003 and 110004.Starting at €0.00
-
Managing Vioxx (A) (Spanish version)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S02Strategy(B) evidence of life-threatening side effects, (C) decision options, (D) announcement to withdraw Vioxx, (E) reaction by patients, shareholders, media, and regulators, (F) Merck fights back, and (G) wrap-up. At the end of the case series, students may conclude that doing the right thing sometimes requires very hard choices.Starting at €8.20
-
Merck: La administración de Vioxx (B)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S03Knowledge and CommunicationStarting at €5.74
-
Merck: La administración de Vioxx (C)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S04Knowledge and CommunicationStarting at €5.74
-
Merck: La administración de Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S06Knowledge and CommunicationStarting at €5.74